Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 38Nivolumab 24atezolizumab 10Ipilimumab 7Carboplatin 6avelumab 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Docetaxel 5Cyclophosphamide 5fludarabine 4cabozantinib 4Specimen Handling 4Pemetrexed 4regorafenib 3Interleukin-2 3Gemcitabine 3130-nm albumin-bound paclitaxel 3spartalizumab 2lenvatinib 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Immune Checkpoint Inhibitors 2Cisplatin 2Biopsy 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × eprenetapopt × Thoracic × Clear all
NCT04383938 2025-05-13

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Aprea Therapeutics

Phase 1/2 Completed
40 enrolled 11 charts
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡